A reactive vaccination campaign with single dose oral cholera vaccine (OCV) during a cholera outbreak in Cameroon

Amani, Adidja; Tatang, Collins A.; Bayiha, Christian N.; Woung, Marcel; Bama, Solange Ngo; Nangmo, Armanda; Mbang, Marie Angèle; Douba, Emmanuel Epee

doi:10.1016/j.vaccine.2021.01.017

Cited by 6 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The vaccine was well accepted, and a high level of coverage was achieved. Two reports revealed that coverage of the OCV campaign conducted in Cox's Bazar among Rohingya Myanmar nationals and the host populations was around/over a hundred percent, which is similar to the OCV campaign conducted in Mozambique in 2016 and Cameroon in 2019 [16,17]. After the successful pre-emptive campaign in the Cox's Bazar humanitarian camps, no cholera outbreaks were detected [18].…”

Section: Discussionmentioning

confidence: 70%

Implementation and Delivery of Oral Cholera Vaccination Campaigns in Humanitarian Crisis Settings among Rohingya Myanmar nationals in Cox’s Bazar, Bangladesh

et al. 2023

View full text Add to dashboard Cite

Background: Over 700,000 Myanmar nationals known as the ‘Rohingyas’ fled into Cox’s Bazar, Bangladesh, in late 2017. Due to this huge displacement into unhygienic areas, these people became vulnerable to communicable diseases including cholera. Assessing the risk, the Government of Bangladesh (GoB), with the help of the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B) and other international partners, decided to take preventive measures, one of which is the execution of oral cholera vaccination (OCV) campaigns. This paper describes the implementation and delivery of OCV campaigns during humanitarian crises in Bangladesh. Methods: Seven rounds of OCV campaigns were conducted between October 2017 and December 2021. The OCV campaigns were conducted by applying different strategies. Results: Approximately 900,000 Rohingya Myanmar nationals (RMNs) and the host population (amounting to 528,297) received OCV across seven campaigns. In total, 4,661,187 doses of OCVs were administered, which included 765,499 doses for RMNs, and 895,688 doses for the host community. The vaccine was well accepted, and as a result, a high level of coverage was achieved, ranging from 87% to 108% in different campaigns. Conclusions: After successful pre-emptive campaigns in Cox’s Bazar humanitarian camps, no cholera outbreaks were detected either in the RMN or host communities.

show abstract

Section: Discussionmentioning

confidence: 70%

Implementation and Delivery of Oral Cholera Vaccination Campaigns in Humanitarian Crisis Settings among Rohingya Myanmar nationals in Cox’s Bazar, Bangladesh

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In areas where cholera is endemic, the WHO recommends cholera vaccination as part of the national cholera control program along with WaSH (10). Several studies have shown that the early introduction of vaccines during an outbreak offers 79% protection against cholera (100, 101), and even one dose of the cholera vaccine significantly reduces the risk (5,(102)(103)(104).…”

Section: Vaccinationmentioning

confidence: 99%

Diagnosis, Management, and Future Control of Cholera

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There are now processes in place to receive and evaluate requests for oral cholera vaccine usage in both outbreak and endemic scenarios. As mentioned above, Bangladesh was the first country to actively investigate this option, and other countries, including Mozambique, South Sudan, Cameroon, Uganda, Nigeria, Somalia, and Malawi, have also implemented mass vaccination campaigns (216)(217)(218)(219)(220)(221)(222). Further success with this approach will require sustained efforts and commitments from numerous humanitarian organizations, including WHO, Gavi, the Vaccine Alliance, local ministries of health, and others.…”

Section: Cholera Vaccine Developmentmentioning

confidence: 99%

Controlled Human Infection Models To Accelerate Vaccine Development

et al. 2022

View full text Add to dashboard Cite

The timelines for developing vaccines against infectious diseases are lengthy, and often vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of protective efficacy. The application of controlled human challenge models of infection and disease at the appropriate stages of development could accelerate development of candidate vaccines and, in fact, has done so successfully in some limited cases.

show abstract

A reactive vaccination campaign with single dose oral cholera vaccine (OCV) during a cholera outbreak in Cameroon

Cited by 6 publications

References 5 publications

Implementation and Delivery of Oral Cholera Vaccination Campaigns in Humanitarian Crisis Settings among Rohingya Myanmar nationals in Cox’s Bazar, Bangladesh

Implementation and Delivery of Oral Cholera Vaccination Campaigns in Humanitarian Crisis Settings among Rohingya Myanmar nationals in Cox’s Bazar, Bangladesh

Diagnosis, Management, and Future Control of Cholera

Controlled Human Infection Models To Accelerate Vaccine Development

Contact Info

Product

Resources

About